Fadie Thomas Coleman

Assistant Professor, Medical Sciences & Education

Fadie Coleman

Other Positions

  • Assistant Professor, Sociomedical Sciences, Boston University School of Medicine

Education

  • Boston University School of Medicine, PhD
  • Harvard University, MA
  • Boston University, BA

Publications

  • Published on 8/15/2017

    Coleman FT, Blahna MT, Kamata H, Yamamoto K, Zabinski MC, Kramnik I, Wilson AA, Kotton DN, Quinton LJ, Jones MR, Pelton SI, Mizgerd JP. Capacity of Pneumococci to Activate Macrophage Nuclear Factor ?B: Influence on Necroptosis and Pneumonia Severity. J Infect Dis. 2017 Aug 15; 216(4):425-435. PMID: 28368460.

    Read at: PubMed
  • Published on 5/17/2017

    Smith NM, Wasserman GA, Coleman FT, Hilliard KL, Yamamoto K, Lipsitz E, Malley R, Dooms H, Jones MR, Quinton LJ, Mizgerd JP. Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia. Mucosal Immunol. 2017 May 17. PMID: 28513594.

    Read at: PubMed
  • Published on 10/9/2014

    Hyatt LD, Wasserman GA, Rah YJ, Matsuura KY, Coleman FT, Hilliard KL, Pepper-Cunningham ZA, Ieong M, Stumpo DJ, Blackshear PJ, Quinton LJ, Mizgerd JP, Jones MR. Myeloid ZFP36L1 does not regulate inflammation or host defense in mouse models of acute bacterial infection. PLoS One. 2014; 9(10):e109072. PMID: 25299049.

    Read at: PubMed
  • Published on 2/5/2007

    Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB. Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun. 2007 Apr; 75(4):1598-608. PMID: 17283089.

    Read at: PubMed
  • Published on 11/1/2004

    Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 1; 173(9):5671-8. PMID: 15494518.

    Read at: PubMed
  • Published on 7/1/2004

    Priebe GP, Dean CR, Zaidi T, Meluleni GJ, Coleman FT, Coutinho YS, Noto MJ, Urban TA, Pier GB, Goldberg JB. The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun. 2004 Jul; 72(7):4224-32. PMID: 15213167.

    Read at: PubMed
  • Published on 7/1/2003

    Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun. 2003 Jul; 71(7):3875-84. PMID: 12819072.

    Read at: PubMed
  • Published on 3/1/2003

    Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun. 2003 Mar; 71(3):1453-61. PMID: 12595463.

    Read at: PubMed
  • Published on 2/10/2003

    Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1949-54. PMID: 12578988.

    Read at: PubMed
  • Published on 3/1/2002

    Priebe GP, Brinig MM, Hatano K, Grout M, Coleman FT, Pier GB, Goldberg JB. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun. 2002 Mar; 70(3):1507-17. PMID: 11854239.

    Read at: PubMed

View 2 more publications: View full profile at BUMC

View all profiles